191 related articles for article (PubMed ID: 20339847)
21. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
[TBL] [Abstract][Full Text] [Related]
22. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer.
Inkoom A; Ndemazie NB; Smith T; Frimpong E; Bulusu R; Poku R; Zhu X; Han B; Trevino J; Agyare E
BMC Cancer; 2023 May; 23(1):435. PubMed ID: 37179357
[TBL] [Abstract][Full Text] [Related]
23. Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1.
Akashi Y; Oda T; Ohara Y; Miyamoto R; Kurokawa T; Hashimoto S; Enomoto T; Yamada K; Satake M; Ohkohchi N
Br J Cancer; 2014 Mar; 110(6):1481-7. PubMed ID: 24556620
[TBL] [Abstract][Full Text] [Related]
24. Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis.
Guo HC; Bu HQ; Luo J; Wei WT; Liu DL; Chen H; Tong HF; Wang ZH; Wu HY; Li HH; Zuo MM; Li W; Lin SZ
Int J Oncol; 2012 Jun; 40(6):1849-57. PubMed ID: 22378302
[TBL] [Abstract][Full Text] [Related]
25. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
Allison Logan S; Brissenden AJ; Szewczuk MR; Neufeld RJ
Drug Des Devel Ther; 2017; 11():2239-2250. PubMed ID: 28814832
[TBL] [Abstract][Full Text] [Related]
26. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract][Full Text] [Related]
27. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
[TBL] [Abstract][Full Text] [Related]
28. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
[TBL] [Abstract][Full Text] [Related]
29. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.
Kimura K; Sawada T; Komatsu M; Inoue M; Muguruma K; Nishihara T; Yamashita Y; Yamada N; Ohira M; Hirakawa K
Clin Cancer Res; 2006 Aug; 12(16):4925-32. PubMed ID: 16914581
[TBL] [Abstract][Full Text] [Related]
30. Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency.
Xin Y; Shen XD; Cheng L; Hong DF; Chen B
Cancer Chemother Pharmacol; 2014 Apr; 73(4):711-9. PubMed ID: 24519751
[TBL] [Abstract][Full Text] [Related]
31. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
32. Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer.
Li J; Wang R; Schweickert PG; Karki A; Yang Y; Kong Y; Ahmad N; Konieczny SF; Liu X
Cell Cycle; 2016; 15(5):711-9. PubMed ID: 26890815
[TBL] [Abstract][Full Text] [Related]
33. Experimental study of combination therapy with S-1 against pancreatic cancer.
Yoshizawa J; Takizawa A; Takeuchi O; Hiraku O; Sasaki K; Morimoto Y; Atsuda K; Inoue G; Suzuki Y; Asanuma F; Yamada Y
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1211-9. PubMed ID: 19337733
[TBL] [Abstract][Full Text] [Related]
34. The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
Yu H; Song H; Xiao J; Chen H; Jin X; Lin X; Pan B; Ji W
Biomed Pharmacother; 2017 Dec; 96():650-658. PubMed ID: 29035831
[TBL] [Abstract][Full Text] [Related]
35. Luteolin and Gemcitabine Protect Against Pancreatic Cancer in an Orthotopic Mouse Model.
Johnson JL; Dia VP; Wallig M; Gonzalez de Mejia E
Pancreas; 2015 Jan; 44(1):144-51. PubMed ID: 25237909
[TBL] [Abstract][Full Text] [Related]
36. Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human pancreatic cancer.
Hiroshima Y; Maawy AA; Katz MH; Fleming JB; Bouvet M; Endo I; Hoffman RM
J Surg Oncol; 2015 Mar; 111(3):311-5. PubMed ID: 25394368
[TBL] [Abstract][Full Text] [Related]
37. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
38. Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines.
Morimoto Y; Takeuchi O; Takizawa A; Yoneyama H; Asanuma F; Suzuki Y; Atsuda K; Yamada Y
Anticancer Drugs; 2012 Jun; 23(5):505-14. PubMed ID: 22334000
[TBL] [Abstract][Full Text] [Related]
39. Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway.
Xiang Y; Ye W; Huang C; Yu D; Chen H; Deng T; Zhang F; Lou B; Zhang J; Shi K; Chen B; Zhou M
Oxid Med Cell Longev; 2018; 2018():2360427. PubMed ID: 29849873
[TBL] [Abstract][Full Text] [Related]
40. Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression.
Wang C; Zhang W; Fu M; Yang A; Huang H; Xie J
Oncol Rep; 2015 Jan; 33(1):383-90. PubMed ID: 25394408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
